Navigation Links
Niiki Pharma Announces Positive Interim Data from Ongoing Clinical Trial of Novel Anti-Cancer Agent NKP-1339
Date:9/20/2011

pNET patients is significant. This activity, together with mild-side effect profile, makes NKP-1339 a potentially promising new treatment for this disease," said Dr. Daniel Von Hoff.

"It is gratifying to see someone whose tumor has been resistant to other therapies do well with this promising investigational therapy. The patient has received NKP-1339 for more than a year and continues to benefit," added Dr. Howard Burris.

"We are pleased by these interim results demonstrating the single agent anti-tumor activity of NKP-1339 in patients with advanced cancers refractory to standard treatments," said Dr. Angela Ogden, Chief Medical Officer for Niiki Pharma Inc.

"The preliminary results of this ongoing trial, showing the anti-tumor activity and the safety profile of NKP-1339, support our preclinical studies that the drug targets tumors selectively and is active against different tumors. We are delighted to see years of research come to fruition in collaboration with Niiki Pharma's team," said Professor Keppler, University of Vienna, inventor of NKP-1339.

About NKP-1339NKP-1339 is a first-in-class transferrin targeted ruthenium-based anti-cancer compound. Transferrin receptor is significantly over-expressed in many tumor types. The intracellular target pathways of NKP-1339 include down-regulation of GRP78, a key regulator of mis-folded protein processing and a tumor survival factor.  GRP78 is the cause of resistance in many tumor types. In preclinical studies, NKP-1339 has demonstrated activity against multiple tumor types, including those resistant to other anti-cancer agents, including platinum-containing agents, anthracyclines and anti-tubulins.

NKP-1339 was invented by Professor Bernard K. Keppler, currently the Dean of the Faculty of Chemistry at University of Vienna, Austria, and Head of the Research Platform "Translational Cancer Therapy Research", a multi-disciplinary collaboration between University of Vienna and th
'/>"/>

SOURCE Niiki Pharma Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novel First-in-Class Anti-Cancer Agent in Development by Niiki Pharma Shows Promising Phase I Results
2. Valeant Pharmaceuticals to Refinance Senior Secured Credit Facilities
3. Nations Pharmacists Ready to Administer Seasonal Flu Vaccines
4. Watson Pharmaceuticals Announces Approval of Amphastars Generic LOVENOX(R)
5. Jazz Pharmaceuticals and Azur Pharma Agree to Combine to Form Jazz Pharmaceuticals plc
6. Pinnacle Biologics Appoints ALKOPHARMA SA Its Exclusive Distributor For PDT (Photodynamic Therapy), in Select European Countries, Middle East And South East Asian Territories
7. Genesis Biopharma Adds Cell Therapy Bioprocess Engineering, Clinical Trial Design, Biostatistics, Regulatory Affairs and FDA Compliance Expertise
8. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on September 28, 2011
9. Pharmasset to Present at Two Upcoming Conferences
10. MDC Partners Launches Integrated Healthcare Marketing Platform With Acquisition of Majority Stake in Concentric Pharma Advertising
11. Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... Inc. (NASDAQ:INSM), a ,biopharmaceutical company focused on the development ... diseases with unmet,medical needs, today announced that it ... Growth,Opportunities Conference in New York City. ... Oriental Hotel in New,York City, will run from ...
... 9, 2007 - Neose Technologies,Inc. (NasdaqGM:NTEC) announced today ... Emerging Growth Opportunities Conference,held at the Mandarin Oriental ... The Company's presentation is scheduled for 2:00 p.m.,(EDT) ... be webcast,live and available for replay via the ...
Cached Medicine Technology:Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference 2
(Date:7/9/2014)... Researchers have found that fecal transplantation is effective ... immunocompromised patients. This is the result of a study ... Center for Women,s Gastrointestinal Medicine at The Women,s Medicine ... online in advance of print in the American ... or C. diff , has increased to epidemic ...
(Date:7/9/2014)... are personal and subjective, the human brain turns ... emotions across different senses, situations and even people, ... Adam Anderson. , "We discovered that fine-grained patterns ... area of the brain associated with emotional processing, ... individual,s subjective feeling," says Anderson, associate professor of ...
(Date:7/9/2014)... 8, 2014) Researchers from Montefiore Medical Center ... of Yeshiva University will present new findings at ... 12 July 17 in Copenhagen, Denmark. Data from ... prompt transition from cognitive normality to mild cognitive impairment ... Einstein Aging Study , established in 1980 to examine ...
(Date:7/9/2014)... smell of flatulence and have a reputation for being highly ... sulfide is now being being found to offer potential health ... heart attacks and dementia. A new compound (AP39), designed and ... to future therapies, by targeting delivery of very small amounts ... cells. , Scientists in Exeter have already found that ...
(Date:7/9/2014)... conducted by researchers at Tufts University School of Dental ... and developmental disabilities, the likelihood of having cavities decreased ... The findings, published in the July/August issue of ... designed to address the oral health of individuals in ... records of 107 patients at one of the eight ...
Breaking Medicine News(10 mins):Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:Study cracks how the brain processes emotions 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3
... , , , WASHINGTON, ... Produce Safety Project: , , We commend the FDA ... The proposed guidance documents put out for comment today address three ... these documents quickly. We also look forward to the agency,s next ...
... ... in Webinar Series on "How Generation and Gender Impact Physician Engagement" , ... Charlotte, N.C. (Vocus) July 31, 2009 -- ... in Physician Engagement." The free hour-long ,webinar will be broadcast on Wednesday, August ...
... SHENZHEN, China, July 31 /PRNewswire-FirstCall/ ... announced today that its,registration dossier for MEVAC-DTaP (Diphtheria, Tetanus ... consideration,of the experts in Thai FDA. The sample analysis ... , Mr. Terry Yuan CEO ...
... , COLUMBIA, S.C., July 31 Amid rising ... benefits of including international medical travel coverage in their employee ... possible risks associated with offering such options. , , ... Global Healthcare Inc. today announced an agreement with an insurer ...
... skills, researchers say , FRIDAY, July 31 (HealthDay News) ... should learn cardiopulmonary resuscitation (CPR), Austrian researchers say. , In ... life-support training, 86 percent of the children performed CPR correctly ... to the report published online in the journal Critical ...
... , , , ... Language Line Services , the leading provider of ... evening, July 23rd at a Recognition and Awards Banquet at Bellevue University, ... Wray, President of the Nebraska Association for Translators & Interpreters (NATI), said, ...
Cached Medicine News:Health News:Webinar on "Physician Engagement - Diagnosing Generational Differences" Presented by Morehead Associates 2Health News:Webinar on "Physician Engagement - Diagnosing Generational Differences" Presented by Morehead Associates 3Health News:Hard to Treat Diseases, Inc. (HTDS) Thai Registration Dossier 2Health News:Hard to Treat Diseases, Inc. (HTDS) Thai Registration Dossier 3Health News:New Policies Protect Employers, Workers Who Choose Global Health Care 2Health News:Even 9-Year-Olds Can Learn CPR 2Health News:Language Line Services Honored by Nebraska Association for Translators & Interpreters (NATI) 2Health News:Language Line Services Honored by Nebraska Association for Translators & Interpreters (NATI) 3
When You Need Optimal Patient Comfort with Minimal Weight at a Nonunion Site...Demand The OrthoPak Noninvasive Bone Growth Stimulator., ,Most Appropriate for the Proximal Femur, Metatarsal/Tarsal...
... Providing the surgical versatility you demand when ... new EBI OsteoGen-D offers 40 microamperes of ... each with 20 microamperes. Available in both ... superior flexibility with any of your bone ...
... cataract surgery following refractive surgery grows larger ... for surgeons, as calculating IOL power for ... power following RK, ALK, PRK and LASIK ... or topography. For example, keratometry and simulated ...
... to offer one of the ... at only 188 grams! The ... superior flow rate with effortless ... The complementing electrodes provide powerful ...
Medicine Products: